BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Feb. 11, 2009
View Archived Issues
New PARP-1 inhibitors with anticancer activity discovered at AstraZeneca
Read More
Novel mGluR2 ligands for schizophrenia and other disorders disclosed by Pfizer researchers
Read More
New MAP kinase inhibitors useful for treating asthma reported in recent AstraZeneca patent
Read More
Recent Merck Frosst patent claims new GPR105 antagonists for type 2 diabetes and obesity
Read More
Novel glucokinase activators jointly reported by Nissan Chemical and Taisho
Read More
New deuterium-enriched clopidogrel analogues under development at Protia
Read More
Microbicide Trials Network releases BufferGel and PRO-2000/5 trial data
Read More
Viralytics initiates head and neck cancer trial with Cavatak
Read More
Winston presents topline civamide patch results
Read More
Q3 highlights at Mitsubishi Tanabe Pharma
Read More
Arete starts phase IIa AR-9281 trial in type 2 diabetes
Read More
Capstone commences dosing in phase II AZX-100 trial in dermal scarring
Read More
SPI-452 inhibits CYP3A in vitro, increases protease inhibitor exposure in humans
Read More
Aeolus initiates studies of AEOL-10150 as a countermeasure to mustard gas exposure
Read More
HIV pharmaco-enhancer GS-9350 inhibits CYP3A and has no antiviral effects
Read More
Cell and IDIS sign collaborative agreement for pixantrone named-patient program
Read More
Dyax and Fovea sign exclusive E.U. license agreement for DX-88 in ophthalmic indications
Read More
FDA accepts Enzon's IND to initiate phase I study of its survivin antagonist
Read More
Cougar reaches agreement with FDA under SPA for phase III clinical trial of CB-7630
Read More
Synta treats first patient in clinical trial of elesclomol for solid tumors
Read More
DiaMedica completes treatment in phase IIa clinical trial of DM-99 in type 2 diabetes
Read More
Merrion completes patient enrolment in phase IIb study of Orazol
Read More
Enzon discontinues rhMBL development
Read More
ConjuChem data confirms PC-DAC lowers glucose in diabetes trials
Read More
Vivus initiates second pivotal phase III avanafil trial for erectile dysfunction
Read More